Covid-19 Respiratory Sequelae French Cohort

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2933 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-07

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

As the investigators need data on long term outcome of Covid-19, especially respiratory sequelae, a national cohort is required. To better evaluate the potential respiratory sequelae after SARS-CoV-2 infection, it is fundamental to include patients with different management at the acute phase of the Covid-19: ambulatory management, hospitalization in non ICU and in ICU units. That is why the investigators will conduct a national cohort study with all components of french pneumology which will give the investigators the opportunity to include patients in general hospital, in university hospital and in private structure. As it is a "real life" study, the investigators will include all patients who will have a consultation with a pneumologist for an evaluation 5 to 7 months after a Covid-19 infection whatever their acute disease management. The investigators will collect all available data on Covid-19 acute phase, on patients characteristics and comorbidities, on persistent symptoms after Covid-19, on exams results during the outcome evaluation (CT-scan, 6 min walk test, spirometry and DLCO, blood gas, VO2 max if realized).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.

NCT04005833

Chronic Obstructive Pulmonary Disease

TERMINATED

COVID 19 Serology in Pulmonologists

NCT04422574

Covid 19

COMPLETED

Pulmonary Fibrosis During Severe COVID-19 Pneumonia

NCT04987528

Severe Acute Respiratory Syndrome Coronavirus 2 Acute Respiratory Distress Syndrome Pulmonary Fibrosis

ACTIVE_NOT_RECRUITING

LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION

NCT04409275

Pulmonary Fibrosis

UNKNOWN

A Cohort of Patients With Phenotyped Diffuse Interstitial Lung Disease With Longitudinal Follow-up

NCT05810493

Interstitial Lung Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Fibrosis Cohort Follow-up Sequelae Spirometry DLCO

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adults, older than 18
* SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) in nasopharyngeal swab in patients who are evaluated by a pneumologist 5 to 7 months after their Covid-19 disease